MCID: OST115
MIFTS: 40

Osteonecrosis of the Jaw

Categories: Bone diseases, Oral diseases, Rare diseases

Aliases & Classifications for Osteonecrosis of the Jaw

MalaCards integrated aliases for Osteonecrosis of the Jaw:

Name: Osteonecrosis of the Jaw 58

Classifications:

Orphanet: 58  
Rare systemic and rhumatological diseases
Rare bone diseases


External Ids:

ICD10 via Orphanet 33 K10.2
UMLS via Orphanet 72 C2711248
Orphanet 58 ORPHA399293

Summaries for Osteonecrosis of the Jaw

MalaCards based summary : Osteonecrosis of the Jaw is related to osteonecrosis and bone resorption disease. An important gene associated with Osteonecrosis of the Jaw is CYP2C8 (Cytochrome P450 Family 2 Subfamily C Member 8), and among its related pathways/superpathways are Innate Immune System and Allograft rejection. The drugs Hormones and Zoledronic Acid have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and prostate, and related phenotypes are digestive/alimentary and liver/biliary system

Wikipedia : 74 Osteonecrosis of the jaw (ONJ) is a severe bone disease (osteonecrosis) that affects the jaws (the... more...

Related Diseases for Osteonecrosis of the Jaw

Diseases related to Osteonecrosis of the Jaw via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 225)
# Related Disease Score Top Affiliating Genes
1 osteonecrosis 32.2 VEGFA NFATC1 FDPS CYP2C8
2 bone resorption disease 31.3 NFATC1 FDPS CYP19A1
3 bone disease 31.0 VEGFA NFATC1 IL17A FDPS CYP19A1
4 periodontitis 30.7 VEGFA IL17A DEFB4A DEFB103B DEFB1
5 myeloma, multiple 30.6 VEGFA SIRT1 IL17A FDPS BCL6
6 bone inflammation disease 30.2 VEGFA IL17A HLA-DRB1
7 neurofibromatosis, type ii 30.1 VEGFA DEFB4A DEFB1
8 bacterial infectious disease 29.9 IL17A DEFB4A DEFB103B DEFB1
9 osteoporosis 29.5 VEGFA TGFB1 SIRT1 NFATC1 IL17A FDPS
10 arthritis 29.2 VEGFA TGFB1 IL17A HLA-DRB1 HLA-DQB1
11 inflammatory bowel disease 28.2 VEGFA TGFB1 NFATC1 IL17A HLA-DRB1 HLA-DQB1
12 systemic lupus erythematosus 27.8 VEGFA TGFB1 SIRT1 IL17A HLA-DRB1 HLA-DQB1
13 gnathodiaphyseal dysplasia 11.3
14 bone mineral density quantitative trait locus 8 10.9
15 bone mineral density quantitative trait locus 15 10.9
16 osteomyelitis 10.8
17 mammary paget's disease 10.8
18 rapidly involuting congenital hemangioma 10.7
19 endosteal hyperostosis, autosomal dominant 10.4
20 triiodothyronine receptor auxiliary protein 10.4
21 bone cancer 10.4
22 renal cell carcinoma, nonpapillary 10.4
23 avascular necrosis 10.4
24 brittle bone disorder 10.3
25 maxillary sinusitis 10.3
26 kidney cancer 10.3
27 rheumatoid arthritis 10.3
28 mucositis 10.3
29 paget's disease of bone 10.3
30 primary cutaneous b-cell lymphoma 10.3 VEGFA BCL6
31 breast cancer 10.3
32 fibrous dysplasia 10.3
33 osteopetrosis 10.3
34 thrombophilia 10.3
35 actinomycosis 10.3
36 47,xyy 10.3
37 mycetoma 10.3 IL17A CYP19A1
38 hypopyon 10.2 VEGFA IL17A
39 follicular lymphoma 1 10.2 HLA-DRB1 BCL6
40 limbic encephalitis with lgi1 antibodies 10.2 HLA-DRB1 HLA-DQB1
41 lymphoproliferative syndrome 10.2
42 rickets 10.2
43 fasciitis 10.2
44 necrotizing fasciitis 10.2
45 paresthesia 10.2
46 autoimmune polyglandular syndrome type 3 10.2 HLA-DRB1 HLA-DQB1
47 hypersomnia 10.2 HLA-DRB1 HLA-DQB1
48 narcolepsy 2 10.2 HLA-DRB1 HLA-DQB1
49 aggressive periodontitis 10.2 IL17A DEFB4A DEFB1
50 primary adrenal insufficiency 10.2 HLA-DRB1 HLA-DQB1

Graphical network of the top 20 diseases related to Osteonecrosis of the Jaw:



Diseases related to Osteonecrosis of the Jaw

Symptoms & Phenotypes for Osteonecrosis of the Jaw

MGI Mouse Phenotypes related to Osteonecrosis of the Jaw:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.8 CYP19A1 HLA-DQB1 IL17A NFATC1 SIRT1 TGFB1
2 liver/biliary system MP:0005370 9.7 BCL6 CYP19A1 HLA-DQB1 NFATC1 SIRT1 TGFB1
3 renal/urinary system MP:0005367 9.5 CYP19A1 HLA-DQB1 IL17A SEMA4D SIRT1 TGFB1
4 respiratory system MP:0005388 9.17 BCL6 HLA-DQB1 IL17A NFATC1 SIRT1 TGFB1

Drugs & Therapeutics for Osteonecrosis of the Jaw

Drugs for Osteonecrosis of the Jaw (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Hormones Phase 4
2
Zoledronic Acid Approved Phase 3 118072-93-8 68740
3
Denosumab Approved Phase 3 615258-40-7
4
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
5
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
6
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
7 Tocotrienol Investigational Phase 3 6829-55-6
8 Ibandronic Acid Phase 3
9 Tocopherols Phase 3
10 Tocotrienols Phase 3
11 Trace Elements Phase 3
12 Micronutrients Phase 3
13 Vitamins Phase 3
14 Phosphodiesterase Inhibitors Phase 3
15 Antioxidants Phase 3
16 Vasodilator Agents Phase 3
17 Platelet Aggregation Inhibitors Phase 3
18 Nutrients Phase 3
19 Protective Agents Phase 3
20 Radiation-Protective Agents Phase 3
21 Mitogens Phase 2, Phase 3
22
Alendronate Approved Phase 1, Phase 2 66376-36-1, 121268-17-5 2088
23 Immunoglobulins Phase 1, Phase 2
24 Antibodies Phase 1, Phase 2
25 Antibodies, Monoclonal Phase 1, Phase 2
26 Pharmaceutical Solutions Phase 2
27
Clavulanate Approved, Vet_approved 58001-44-8 5280980
28
Amoxicillin Approved, Vet_approved 26787-78-0 33613
29
Clindamycin Approved, Vet_approved 18323-44-9 29029
30
Tetracycline Approved, Vet_approved 60-54-8 5353990
31
Phenytoin Approved, Vet_approved 57-41-0 1775
32
Pamidronate Approved 40391-99-9 4674
33
Parathyroid hormone Approved, Investigational 9002-64-6
34
Teriparatide Approved, Investigational 52232-67-4 16133850
35
Clotrimazole Approved, Vet_approved 23593-75-1 2812
36
Miconazole Approved, Investigational, Vet_approved 22916-47-8 4189
37
Risedronate Approved, Investigational 105462-24-6 5245
38
Etidronic acid Approved 2809-21-4, 7414-83-7 3305
39
tiludronate Approved, Investigational, Vet_approved 89987-06-4 60937
40
Vitamin D3 Approved, Nutraceutical 67-97-0 5280795 6221
41 Clindamycin phosphate
42 Clindamycin palmitate
43 Amoxicillin-Potassium Clavulanate Combination
44 beta-Lactamase Inhibitors
45 Anti-Infective Agents
46 Sodium Channel Blockers
47 Anticonvulsants
48 Diuretics, Potassium Sparing
49 Tin Fluorides
50 Diphosphonates

Interventional clinical trials:

(show all 36)
# Name Status NCT ID Phase Drugs
1 A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety Completed NCT00434447 Phase 4 Zoledronic acid
2 Zoledronate Versus Ibandronate Comparative Evaluation: A Randomized Phase III, Open-Label, Multicenter, Parallel Group Clinical Trial to Evaluate and Compare the Efficacy, Safety Profile and Tolerability of Oral Ibandronate Versus Intravenous Zoledronate in the Treatment of Breast Cancer Patients With Bone Metastases Unknown status NCT00326820 Phase 3 ibandronate sodium;zoledronic acid;Zolendronic Acid
3 A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer Completed NCT00869206 Phase 3 zoledronic acid
4 Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial Recruiting NCT02051218 Phase 3 Denosumab (reduced dosing);Denosumab (standard dosing)
5 Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ): A Prospective, Randomized Controlled Trial to Evaluate a Novel Non-operative Treatment Enrolling by invitation NCT03040778 Phase 3 Pentoxifylline;Placebo;Tocopherol
6 Plasma Rich in Growth Factors for Treatment of Medication Related Osteonecrosis of the Jaw: a Multicenter, Randomized, Clinical Trial Not yet recruiting NCT03390777 Phase 2, Phase 3
7 Denosumab (A Monoclonal Antibody to Receptor Activator of Nuclear Factor-Kappa B Ligand (RANKL) in Crohn's Disease Completed NCT02321280 Phase 1, Phase 2 Denosumab
8 Reduced Dose-density of Denosumab for Maintenance Therapy of Unresectable Giant Cell Tumor of Bone: a Multicenter Phase II Study "REDUCE" Recruiting NCT03620149 Phase 2 Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
9 Evaluation of Topical Application of Alendronate Sodium In-situ Gel and Recombinant Human Bone Morphogenic Protein 2 on Dental Implant Stability and Crestal Bone Level: A Randomized Controlled Clinical Study Enrolling by invitation NCT04140006 Phase 1, Phase 2 ALN Gel;BMP Gel;Mixed Gel;Control
10 Phase I Clinical Trial of Use of Autologous Bone Marrow Stem Cells Seeded on Porous Tricalcium Phosphate Matrix and Demineralized Bone Matrix in Patients With Osteonecrosis (MSC/ONM) Unknown status NCT02566681 Phase 1
11 Effect of Denosumab in Reversing Periprosthetic Bone Loss Following Hip Replacement Unknown status NCT02444585 Phase 1 Denosumab
12 Randomized Controlled Trial of Hyperbaric Oxygen in Patients Who Have Taken Bisphosphonates Completed NCT00462098 Phase 1
13 Performance Evaluation of the Micromedic BRONJ Risk Assessment in Vitro Diagnostic Assay. Unknown status NCT02218554
14 Prospective Randomized Clinical Study: Role of Platelet Rich Fibrin (PRF) in the Tooth Extraction Site in the Prevention of Jaw Osteonecrosis on Patients Under Bisphosphonates Therapy Unknown status NCT02198001 tooth extraction with antibiotics (amoxicillin- clavulanate, clindamycine)
15 Changes in Biochemical Markers of Bone Turnover (Serum CTX and PlNP) After Initiation of a "Drug Holiday" From Bisphosphonates Unknown status NCT02575157
16 A Non-interventional Pharmacovigilance Study of Osteonecrosis of the Jaw and Infection Leading to Hospitalization Among Patients With Cancer Treated With XGEVA™ or Zoledronic Acid in Sweden, Denmark, and Norway Completed NCT01967160
17 Efficacy and Safety on the Use of Bisphosphonates in Paediatrics Completed NCT04012320
18 Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer Completed NCT01325142
19 Trans-PBRN Case-control Study of Osteonecrosis of the Jaws Completed NCT01130389
20 S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment Completed NCT00874211
21 Retrospective Cohort Study of ONJ Completed NCT01201330
22 Survey of Oncology Practitioners Prescribing XGEVA® in Europe to Evaluate Their Knowledge of XGEVA® Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw Completed NCT01998607
23 Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer: Concordance Study Completed NCT00858585
24 Bisphosphonate-Associated Jaw Osteonecrosis and PET Imaging Completed NCT00592982
25 Root Canal Treatment of Compromised Teeth as Alternative Treatment in Patients Under Bisphosphonate Therapy: 60-month Results of a Prospective Clinical Study Completed NCT04399720
26 Does Topical Phenytoin Enhance Healing Process in Bisphosphonate-related Osteonecrosis of the Mandible. A Uni-blind Clinical Trial Study Completed NCT03269214 Topical Phenytoin 5%
27 Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic Castration Resistant Prostate Cancer Completed NCT01062503 Zoledronic acid
28 Predictive Value of Bone Turnover Markers During Discontinuation With Alendronate Completed NCT03051620 Discontinue alendronate
29 International, Multicenter, Prospective Registry to Collect Data of Treatment Patterns of Patients With Medication-related Osteonecrosis of the Jaw (MRONJ) and Their Outcome Recruiting NCT02932501
30 Biomarker Identification in Orthopaedic and Oral Maxillofacial Subjects Recruiting NCT01875458
31 Prospective Registry of Prosthodontic Rehabilitation in Oncology Patients Undergoing Jaw Reconstruction Recruiting NCT02661139
32 The Oral Microbiome as a Prognostic Tool in Oral Malignant and Premalignant Lesions and in Medication Related Osteonecrosis of the Jaw Recruiting NCT03418454
33 The Effects of Bovine Colostrum in Bone Metabolism in Humans Recruiting NCT04040010
34 Does Hyperbaric Oxygen Therapy (HBOT) Reduce Pain, Improve Depression and Impact on Patients' Quality of Life for Those Suffering From Late Radiation Tissue Injury? Recruiting NCT02425215
35 Osteonecrosis of the Jaw (ONJ) Case Registry Active, not recruiting NCT01666106
36 POPULATION PHARMACOMETRICS FOR ASSESSING RISK OF BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAW (BRONJ) Withdrawn NCT02069340 zoledronic acid

Search NIH Clinical Center for Osteonecrosis of the Jaw

Genetic Tests for Osteonecrosis of the Jaw

Anatomical Context for Osteonecrosis of the Jaw

MalaCards organs/tissues related to Osteonecrosis of the Jaw:

40
Bone, Breast, Prostate, Bone Marrow, Endothelial, T Cells, Lung

Publications for Osteonecrosis of the Jaw

Articles related to Osteonecrosis of the Jaw:

(show top 50) (show all 2252)
# Title Authors PMID Year
1
Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents. 61
32011077 2020
2
The feasibility of locating the affected bone of BRONJ with indocyanine green. 61
32031311 2020
3
Bisphosphonate-related osteonecrosis of the jaw: Current clinical significance and treatment strategy review. 61
32470236 2020
4
Bisphosphonate-Induced Osteonecrosis of the Jaws (BIONJ). 61
32346224 2020
5
Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis. 61
32524500 2020
6
Changing face of medication-related osteonecrosis of the jaw: Sheba Medical Center experience-fifteen years. 61
32507944 2020
7
Indigenous Microbiota Protects against Inflammation-Induced Osteonecrosis. 61
32109361 2020
8
Laser surgery in management of medication-related osteonecrosis of the jaws: a meta-analysis. 61
32056052 2020
9
Medication-Related Osteonecrosis of the Jaw in Patients Taking High-Dose Simvastatin. 61
32061632 2020
10
Surgical Management of Medication-Related Osteonecrosis of the Jaw Patients Related to Dental Implants. 61
32102027 2020
11
Rituximab as a trigger factor of medication-related osteonecrosis of the jaw. A case report. 61
31301390 2020
12
Positive effect of pentoxifylline on medication-related osteonecrosis of the jaw. 61
31863928 2020
13
Awareness among patient at risk of developing Medication Related Osteonecrosis of the Jaw (MRONJ) - A primary prevention strategy. 61
32550810 2020
14
A drug holiday reduces the frequency and severity of Medication Related Osteonecrosis of the jaw in a minipig model. 61
32568416 2020
15
Case reports of medication-related osteonecrosis of the jaw (MRONJ) treated with uncultured stromal vascular fraction and L-PRF. 61
32540361 2020
16
Emerging therapies with potential risks of medicine-related osteonecrosis of the jaw: a review of the literature. 61
32541753 2020
17
Distinct immunopathology in the early stages between different antiresorptives-related osteonecrosis of the jaw-like lesions in mice. 61
32142911 2020
18
Quantitative evaluation of anti-resorptive agent-related osteonecrosis of the jaw using bone single photon emission computed tomography in clinical settings: relationship between clinical stage and imaging. 61
32557015 2020
19
Comment on "The Effect of Platelet-Rich Fibrin Membrane in Surgical Therapy of Medication-Related Osteonecrosis of the Jaw" by Szentpeteri et al. 61
32504560 2020
20
Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study. 61
32536575 2020
21
Zoledronate Inhibits Osteoclast Differentiation via Suppressing Vascular Endothelial Growth Factor Receptor 2 Expression. 61
32274606 2020
22
Computed tomography imaging features of osteomyelitis of the jaw: comparison between antiresorptive medication-related conditions and medication-unrelated conditions. 61
31983632 2020
23
Influence of ridge preservation procedures on extraction socket healing under antiresorptive therapy: An experimental study in rabbits. 61
32537909 2020
24
Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. 61
32535678 2020
25
Assessment of inflammatory jaw pathologies using bone SPECT/CT maximum standardized uptake value. 61
32491931 2020
26
A cutaneous presentation of bisphosphonate-related osteonecrosis of the jaw. 61
32412657 2020
27
Medication-Related Osteonecrosis of the Jaw in a Duchenne Muscular Dystrophy Patient. 61
32445961 2020
28
History of alendronate. 61
32437874 2020
29
Alendronate or Zoledronic acid do not impair wound healing after tooth extraction in postmenopausal women with osteoporosis. 61
32404281 2020
30
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. 61
32427503 2020
31
Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study. 61
31468192 2020
32
Differences between auto-fluorescence and tetracycline-fluorescence in medication-related osteonecrosis of the jaw-a preclinical proof of concept study in the mini-pig. 61
32444918 2020
33
A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers. 61
32408510 2020
34
Cervical abscess as an exceptional presentation of advance bisphosphonate-related osteonecrosis of the jaw: Case report and review of the literature. 61
29691163 2020
35
Autologous platelet-rich fibrin injections in the management of facial cutaneous sinus tracts secondary to medication-related osteonecrosis of the jaw. 61
32219975 2020
36
Which symptoms negatively affect the oral health-related quality of life in patients with osteonecrosis of the jaw? 61
32493679 2020
37
The Effect of Platelet-Rich Fibrin Membrane in Surgical Therapy of Medication-Related Osteonecrosis of the Jaw. 61
31945309 2020
38
Necrotizing periodontitis or medication-related osteonecrosis of the jaw (MRONJ) in a patient receiving Bemcentinib-a case report. 61
32440898 2020
39
Risk assessment of bisphosphonate-related osteonecrosis of the jaw based on CBCT scans 61
32427571 2020
40
Surgical Treatment of Osteonecrosis of the Jaw: An Emerging Problem in the Era of Bisphosphonates. 61
32004467 2020
41
Aminobisphosphonate-treated ewes as a model of osteonecrosis of the jaw and of dental implant failure. 61
31755105 2020
42
Pulpal disease arising from medication-related osteonecrosis of the jaw: A case report. 61
32437788 2020
43
Bone-Specific Drugs and Osteonecrosis of Sites Other Than the Jaw: A Nationwide Cohort Study. 61
32379370 2020
44
Medication-related osteonecrosis of the jaw related to epacadostat and pembrolizumab. 61
32413422 2020
45
Borate bioactive glass prevents zoledronate-induced osteonecrosis of the jaw by restoring osteogenesis and angiogenesis. 61
32436640 2020
46
Allogeneic Bone Marrow Mesenchymal Stem Cell Transplantation in Tooth Extractions Sites Ameliorates the Incidence of Osteonecrotic Jaw-Like Lesions in Zoledronic Acid-Treated Rats. 61
32486396 2020
47
Favorable skeletal benefit/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed. 61
32092479 2020
48
Synthetic Hydroxyapatite Inhibits Bisphosphonate Toxicity to the Oral Mucosa In Vitro. 61
32369961 2020
49
Vitamin D Deficiency and Oral Health: A Comprehensive Review. 61
32438644 2020
50
Extracorporeal Shock-Wave Therapy or Low-Level Laser Therapy: Which is More Effective in Bone Healing in Bisphosphonate Treatment? 61
32371691 2020

Variations for Osteonecrosis of the Jaw

Expression for Osteonecrosis of the Jaw

Search GEO for disease gene expression data for Osteonecrosis of the Jaw.

Pathways for Osteonecrosis of the Jaw

GO Terms for Osteonecrosis of the Jaw

Cellular components related to Osteonecrosis of the Jaw according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 VEGFA TGFB1 SEMA4D IL17A HLA-DRB1 DEFB4A
2 MHC class II protein complex GO:0042613 9.16 HLA-DRB1 HLA-DQB1
3 Golgi lumen GO:0005796 8.92 TGFB1 DEFB4A DEFB103B DEFB1

Biological processes related to Osteonecrosis of the Jaw according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.87 VEGFA TGFB1 SIRT1 RBMS3
2 cytokine-mediated signaling pathway GO:0019221 9.86 VEGFA TGFB1 IL17A BCL6
3 negative regulation of cell growth GO:0030308 9.77 TGFB1 SIRT1 BCL6
4 defense response to Gram-positive bacterium GO:0050830 9.75 DEFB4A DEFB103B DEFB1
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.71 VEGFA TGFB1 SEMA4D
6 defense response to Gram-negative bacterium GO:0050829 9.67 DEFB4A DEFB103B DEFB1
7 immune response GO:0006955 9.63 SEMA4D IL17A HLA-DRB1 HLA-DQB1 DEFB4A DEFB1
8 antimicrobial humoral response GO:0019730 9.61 DEFB4A DEFB103B DEFB1
9 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.58 VEGFA TGFB1
10 positive regulation of regulatory T cell differentiation GO:0045591 9.55 TGFB1 BCL6
11 positive chemotaxis GO:0050918 9.54 VEGFA DEFB4A DEFB103B
12 positive regulation of vascular permeability GO:0043117 9.52 VEGFA TGFB1
13 positive regulation of histone deacetylation GO:0031065 9.51 TGFB1 BCL6
14 positive regulation of blood vessel endothelial cell migration GO:0043536 9.5 VEGFA TGFB1 SIRT1
15 positive regulation of cellular component movement GO:0051272 9.48 VEGFA BCL6
16 positive regulation of smooth muscle cell differentiation GO:0051152 9.46 TGFB1 SIRT1
17 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.4 HLA-DRB1 HLA-DQB1
18 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.26 HLA-DRB1 HLA-DQB1
19 macrophage differentiation GO:0030225 9.13 VEGFA SIRT1 HLA-DRB1
20 positive regulation of protein phosphorylation GO:0001934 9.02 VEGFA TGFB1 SIRT1 SEMA4D HLA-DRB1

Molecular functions related to Osteonecrosis of the Jaw according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 9.16 HLA-DRB1 HLA-DQB1
2 chemoattractant activity GO:0042056 9.13 VEGFA DEFB4A DEFB103B
3 CCR6 chemokine receptor binding GO:0031731 8.8 DEFB4A DEFB103B DEFB1

Sources for Osteonecrosis of the Jaw

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....